| abstract |
The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFPβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression. |